Barclays PLC Grows Stock Position in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

Barclays PLC increased its stake in shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) by 226.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,354 shares of the company's stock after purchasing an additional 39,102 shares during the quarter. Barclays PLC owned 0.12% of CARGO Therapeutics worth $1,039,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CRGX. BNP Paribas Financial Markets raised its holdings in shares of CARGO Therapeutics by 437.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company's stock valued at $211,000 after purchasing an additional 9,311 shares in the last quarter. SG Americas Securities LLC purchased a new position in CARGO Therapeutics in the third quarter valued at $234,000. MetLife Investment Management LLC raised its stake in CARGO Therapeutics by 59.3% in the third quarter. MetLife Investment Management LLC now owns 19,833 shares of the company's stock valued at $366,000 after buying an additional 7,380 shares in the last quarter. Rhumbline Advisers raised its stake in CARGO Therapeutics by 14.0% in the second quarter. Rhumbline Advisers now owns 30,639 shares of the company's stock valued at $503,000 after buying an additional 3,765 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of CARGO Therapeutics by 11.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 69,171 shares of the company's stock worth $1,136,000 after acquiring an additional 7,146 shares in the last quarter. Hedge funds and other institutional investors own 93.16% of the company's stock.

CARGO Therapeutics Stock Up 4.8 %

CRGX traded up $0.66 during trading on Tuesday, hitting $14.42. 148,285 shares of the stock were exchanged, compared to its average volume of 258,751. CARGO Therapeutics, Inc. has a 1-year low of $12.17 and a 1-year high of $33.92. The stock has a fifty day moving average price of $17.52 and a two-hundred day moving average price of $17.79. The firm has a market capitalization of $663.72 million and a P/E ratio of -3.38.

CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.26. Analysts predict that CARGO Therapeutics, Inc. will post -3.73 EPS for the current year.

Analyst Upgrades and Downgrades

CRGX has been the topic of several research analyst reports. William Blair began coverage on CARGO Therapeutics in a research report on Tuesday, November 26th. They set an "outperform" rating on the stock. HC Wainwright reissued a "buy" rating and set a $33.00 price objective on shares of CARGO Therapeutics in a report on Friday, November 15th. Finally, Chardan Capital restated a "buy" rating and set a $28.00 price objective on shares of CARGO Therapeutics in a research report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $31.80.

CARGO Therapeutics Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.